Mylan wins FDA approval for generic acid reflux drug

Posted on: Thu, 12 Nov 2009 09:56:00 EST


Symbols: MXLBF
Nov 12, 2009 (Datamonitor via COMTEX) --
MXLBF | Quote | Chart | News | PowerRating -- Mylan, a US-based generic pharmaceutical company, has reported that its Indian subsidiary, Matrix Laboratories, has received final approval from the FDA for its abbreviated new drug application for lansoprazole delayed-release capsules, 15mg and 30mg.

Lansoprazole delayed-release capsules will be sold under the Mylan Pharmaceuticals brand.

Lansoprazole delayed-release (DR) capsules are the generic version of Tap Pharmaceuticals's proton pump inhibitor Prevacid DR capsules.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

For full details on (MXLBF) MXLBF. (MXLBF) has Short Term PowerRatings at TradingMarkets. Details on (MXLBF) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.